Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: US Proposal to Ban Adoption of CN Clinical Trial Data Has Low Possibility to Pass into Law
Recommend 19 Positive 31 Negative 9 |
||||
|
||||
|
According to Endpoints News, on last Thursday (30 April), the US House Appropriations Committee approved a draft report urging the US Food and Drug Administration (FDA) to prohibit the use of clinical trial data generated in China in future drug development applications, including Investigational New Drug (IND) applications, Citi Research issued a research report saying. The broker believed that the likelihood of the draft ultimately being passed into law is low as China's more efficient clinical trial environment is also helping global multinational pharmaceutical companies refill their drug development pipelines with high quality and speed; commercialization of 'Chinese molecules' in the US ultimately needs to conduct late-stage trials in the US, with substantial enrollment of US patients, and approvals are likewise based on US data. Citi Research will host an expert call on the topic tonight (4th) Hong Kong time and will release more details soon. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
